Program
SCTB41
A development code. Also written as “SCTB41+SCTB39G” and “SCTB41+SCTB39-1”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Lymphoma, Non-Hodgkin, led by Sinocelltech Group.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sinocelltech Group | 66 open or running | phase 3since Jun 16, 2026 | Sep 12, 2024 | Apr 30, 2027phase 2 · NCT06600022 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Sep 12, 2024First study: phase 2 study in Advanced Malignant Solid TumoursFirst studyNCT06600022 · 441 planned · China
- May 11, 20262 phase 2 studiesNCT07594028, NCT07609251
- Jun 16, 2026Phase 3 study in Carcinoma, Non-Small-Cell LungPhase 3 reachedNCT07662395 · 410 planned · China
- Jun 18, 2026Phase 2 study in Advanced Malignant Solid TumorsNCT07665970 · 112 planned
- Sep 8, 2026Phase 2 study in Lymphoma, Non-HodgkinNCT07819188 · 90 planned · China
Ahead
- Apr 30, 2027Primary completion: phase 2 study in Advanced Malignant Solid TumoursNCT06600022
- Sep 30, 2028Primary completion: phase 2 study in Lymphoma, Non-HodgkinNCT07819188
- Oct 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07609251
- May 30, 2029Primary completion: phase 2 study in Advanced Malignant Solid TumorNCT07594028
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 6 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07819188Lymphoma, Non-Hodgkin · China | 2 | Not yet recruiting | Sep 30, 2028 | 90 |
| NCT07665970Advanced Malignant Solid Tumors | 2 | Not yet recruiting | Jun 30, 2029 | 112 |
| NCT07662395Carcinoma, Non-Small-Cell Lung · China | 3 | Recruiting | Jan 24, 2030 | 410 |
| NCT07609251Carcinoma, Non-Small-Cell Lung · China | 2 | Not yet recruiting | Oct 2028 | 90 |
| NCT07594028Advanced Malignant Solid Tumor | 2 | Not yet recruiting | May 30, 2029 | 126 |
| NCT06600022Advanced Malignant Solid Tumours · China | 2 | Recruiting | Apr 30, 2027 | 441 |
How it is read
Names in the registry
- “SCTB41”, 4 entries
- “SCTB41+SCTB39G”, 1 entry
- “SCTB41+SCTB39-1”, 1 entry
Codes read as this program: SCTB41.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 2 studies
- Lymphoma, Non-Hodgkin, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.